Immunocore Holdings plc
IMCRDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
IMCR Earnings Report
EPS Est: $-0.01 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How IMCR's past catalysts played out
Brenetafusp
Select Advanced Solid Tumors
Tebentafusp
Advanced Melanoma
IMC-R117C
Cancer
Dacarbazine
Uveal Melanoma
IMCgp100
Uveal Melanoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Brenetafusp | Phase 3 | Select Advanced Solid Tumors | - | - |
Tebentafusp | Phase 3 | Advanced Melanoma | - | - |
IMC-R117C | Phase 2 | Cancer | - | - |
Dacarbazine | Phase 2 | Uveal Melanoma | - | - |
IMCgp100 | Phase 2 | Uveal Melanoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Immunocore Holdings plc's drug pipeline?→
CatalystAlert tracks 5 drug candidates in Immunocore Holdings plc's (IMCR) pipeline across Phase 3, Phase 2. Its lead program is Brenetafusp (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Immunocore Holdings plc's next FDA catalyst?→
Immunocore Holdings plc's (IMCR) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMCR biotech catalysts?→
Add IMCR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immunocore Holdings plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.